MAXCYTE, INC.·4

Nov 16, 7:14 PM ET

Masoud Maher 4

4 · MAXCYTE, INC. · Filed Nov 16, 2021

Insider Transaction Report

Form 4
Period: 2021-11-12
Masoud Maher
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-11-1618,5620 total
    Exercise: $3.25Exp: 2027-07-14Common Stock (18,562 underlying)
  • Exercise/Conversion

    Common Stock

    2021-11-12$2.08/sh+25,722$53,50225,722 total
  • Exercise/Conversion

    Common Stock

    2021-11-15$3.25/sh+6,438$20,92430,716 total
  • Sale

    Common Stock

    2021-11-15$12.16/sh30,716$373,5070 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-11-1524,27875,000 total
    Exercise: $2.08Exp: 2030-02-25Common Stock (24,278 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-11-156,43818,562 total
    Exercise: $3.25Exp: 2027-07-14Common Stock (6,438 underlying)
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-11-1225,72299,278 total
    Exercise: $2.08Exp: 2030-02-25Common Stock (25,722 underlying)
  • Sale

    Common Stock

    2021-11-12$12.66/sh25,722$325,6410 total
  • Exercise/Conversion

    Common Stock

    2021-11-15$2.08/sh+24,278$50,49824,278 total
  • Exercise/Conversion

    Common Stock

    2021-11-16$3.25/sh+18,562$60,32718,562 total
  • Sale

    Common Stock

    2021-11-16$12.08/sh18,562$224,2290 total
Footnotes (6)
  • [F1]This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  • [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  • [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  • [F5]The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on March 25, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date.
  • [F6]This option is fully vested and exercisable.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION